País: Canadá
Língua: inglês
Origem: Health Canada
DAPAGLIFLOZIN
LABORATOIRE RIVA INC.
A10BK01
DAPAGLIFLOZIN
10MG
TABLET
DAPAGLIFLOZIN 10MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0156370002; AHFS:
APPROVED
2023-05-15
_ _ _RIVA-DAPAGLIFLOZIN (dapagliflozin) _ _Page 1 of 72 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr RIVA-DAPAGLIFLOZIN Dapagliflozin Tablets Tablets, 5 mg and 10 mg, Oral ATC Code: A10BK01 Sodium-glucose co-transporter 2 (SGLT2) inhibitors LABORATOIRE RIVA INC. 660 Boul. Industriel Blainville, Quebec J7C 3V4 www.labriva.com Date of Initial Authorization: July 11, 2022 Submission Control Number: 254745 _ _ _RIVA-DAPAGLIFLOZIN (dapagliflozin) _ _Page 2 of 72 _ RECENT MAJOR LABEL CHANGES Not applicable TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations ............................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment ....................................................... 6 4.5 Missed Dose ..................................................................................... Leia o documento completo